BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 7049347)

  • 1. Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group Trial.
    Tormey DC; Gelman R; Band PR; Sears M; Rosenthal SN; DeWys W; Perlia C; Rice MA
    Cancer; 1982 Oct; 50(7):1235-44. PubMed ID: 7049347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial.
    Tormey DC; Gray R; Gilchrist K; Grage T; Carbone PP; Wolter J; Woll JE; Cummings FJ
    Cancer; 1990 Jan; 65(2):200-6. PubMed ID: 2403834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy of advanced breast cancer: a randomized trial of vincristine, Adriamycin, and cyclophosphamide (VAC) versus cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP).
    Carmo-Pereira J; Costa FO; Henriques E
    Cancer; 1981 Oct; 48(7):1517-21. PubMed ID: 7026020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisolone rapidly alternating with doxorubicin and vincristine (CMFP/AV) in advanced breast cancer.
    Rischin D; Bishop JF; Olver IN; Laidlaw CR; Zimet A; Jeal P; Dipell JF
    Am J Clin Oncol; 1992 Oct; 15(5):392-4. PubMed ID: 1524039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors.
    Cummings FJ; Gelman R; Horton J
    J Clin Oncol; 1985 Jul; 3(7):932-40. PubMed ID: 3894587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized clinical trial of CFP versus CMFP in women with metastatic breast cancer.
    Marschke RF; Ingle JN; Schaid DJ; Krook JE; Mailliard JA; Cullinan SA; Pfeifle DM; Votava HJ; Ebbert LP; Windschitl HE
    Cancer; 1989 May; 63(10):1931-7. PubMed ID: 2649221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low dose chemotherapy of metastatic breast cancer with cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil (CAMF) versus sequential cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and adriamycin.
    Creech RH; Catalano RB; Harris DT; Engstrom PF; Grotzinger PJ
    Cancer; 1979 Jan; 43(1):51-9. PubMed ID: 367574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective evaluation of chemohormonal therapy remission maintenance in advanced breast cancer.
    Tormey DC; Gelman R; Band PR; Sears M; Bauer M; Arseneau JC; Falkson G
    Breast Cancer Res Treat; 1981; 1(2):111-9. PubMed ID: 7348567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative chemotherapy and chemohormonal therapy in women with node-positive breast cancer.
    Tormey DC; Gray R; Taylor SG; Knuiman M; Olson JE; Cummings FJ
    NCI Monogr; 1986; (1):75-80. PubMed ID: 3534593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand.
    Bishop JF; Dewar J; Toner G; Tattersall MH; Olver I; Ackland S; Kennedy I; Goldstein D; Gurney H; Walpole E; Levi J; Stephenson J
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-5-S17-9. PubMed ID: 9374084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B.
    Aisner J; Weinberg V; Perloff M; Weiss R; Perry M; Korzun A; Ginsberg S; Holland JF
    J Clin Oncol; 1987 Oct; 5(10):1523-33. PubMed ID: 3655855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Six-year results of the Eastern Cooperative Oncology Group trial of observation versus CMFP versus CMFPT in postmenopausal patients with node-positive breast cancer.
    Taylor SG; Knuiman MW; Sleeper LA; Olson JE; Tormey DC; Gilchrist KW; Falkson G; Rosenthal SN; Carbone PP; Cummings FJ
    J Clin Oncol; 1989 Jul; 7(7):879-89. PubMed ID: 2661734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. International (Ludwig) Breast Cancer Study Group.
    Marini G; Murray S; Goldhirsch A; Gelber RD; Castiglione-Gertsch M; Price KN; Tattersall MH; Rudenstam CM; Collins J; Lindtner J; Cavalli F; Cortés-Funes H; Gudgeon A; Forbes JF; Galligioni E; Coates AS; Senn HJ
    Ann Oncol; 1996 Mar; 7(3):245-50. PubMed ID: 8740787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study.
    Taylor SG; Kalish LA; Olson JE; Cummings F; Bennett JM; Falkson G; Tormey DC; Carbone PP
    J Clin Oncol; 1985 Feb; 3(2):144-54. PubMed ID: 3881561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer.
    Tormey DC; Weinberg VE; Holland JF; Weiss RB; Glidewell OJ; Perloff M; Falkson G; Falkson HC; Henry PH; Leone LA
    J Clin Oncol; 1983 Feb; 1(2):138-45. PubMed ID: 6366133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adriamycin combinations in advanced breast cancer. A Southwest Oncology Group Study.
    Tranum BL; McDonald B; Thigpen T; Vaughn C; Wilson H; Maloney T; Costanzi J; Bickers J; el Mawli NG; Palmer R; Hoogstraten B; Heilburn L; Rasmusen S
    Cancer; 1982 Mar; 49(5):835-9. PubMed ID: 7037152
    [No Abstract]   [Full Text] [Related]  

  • 17. Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. A prospective randomized study.
    Cocconi G; De Lisi V; Boni C; Mori P; Malacarne P; Amadori D; Giovanelli E
    Cancer; 1983 Feb; 51(4):581-8. PubMed ID: 6336981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer: a randomized trial.
    Muss HB; White DR; Richards F; Cooper MR; Stuart JJ; Jackson DV; Rhyne L; Spurr CL
    Cancer; 1978 Nov; 42(5):2141-8. PubMed ID: 363253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment.
    Falkson G; Gelman RS; Pandya KJ; Osborne CK; Tormey D; Cummings FJ; Sledge GW; Abeloff MD
    J Clin Oncol; 1998 May; 16(5):1669-76. PubMed ID: 9586877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective evaluation of rotating chemotherapy in advanced breast cancer. An Eastern Cooperative Oncology Group Trial.
    Tormey D; Gelman R; Falkson G
    Am J Clin Oncol; 1983 Feb; 6(1):1-18. PubMed ID: 6340458
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.